Lung Cancer - Cerba Research

What Is Lung Cancer?

Lung cancer is a devastating disease for patients and their families, and is the leading cause of cancer death worldwide, more than breast and prostate cancer combined (1). The two main lung cancer types are non-small cell lung cancer (NSCLC 80-85%) and small cell lung cancer (SCLC 15%), a more aggressive cancer when compared to NSCLC (2, 3).

Lung cancer is complexified by various histopathologies (e.g., adenocarcinoma, squamous, large cell, and more) and numerous clinically meaningful biomarkers that need to be assessed to provide the best treatment or select the right trial for patients (e.g., EGFR, ALK, ROS1, and more) (4). Cerba Research offers a wide range of histopathology and clinically meaningful biomarker capabilities that can be detected with cutting-edge techniques. Contact us to find out more.

Cerba Research Lung Cancer Services

Our lung cancer specialists support a wide range of lung studies from discovery / preclinical (data not shown) to phase III registration trials and beyond. Most of our projects include specialty testing, such as, but not limited to, NGS broad-panel assays, ctDNA panels, 250+ IHC simplex and multiplex protocols, fluorescence in situ hybridization (FISH), and even NanoString®.

IHC Validation: PD-L1 (22C3) Pharmdx On NSCLC (Dako Omnis Platform)

Our Experience In The Lung Cancer Landscape

638

NGS broad-panel assay with our OncoSign 600+

50

Genes with our OncoSign ctDNA panel

250+

Histopathology analysis with biomarkers such as ALK, c-MET, PD-L1 run in CLIA accredited laboratories

3

Validated PD-L1 clones (e.g. 22C3, SP142, SP263)

Our Areas Of Expertise In Lung Cancer

Did you know that we can cover for your lung cancer biomarker needs? Check out our mapping exercise by selecting lung biomarkers against our Cerba Research offerings with three techniques (NGS, IHC, FISH) (4, 5, 6). Interested in artificial intelligence (AI) image analysis for your lung cancer trial? Check out our resources here.

What Are Lung Cancer Guidelines Proposing? Aligned with Cerba Research Offerings

Lung Cancer Biomarkers	Most Commonly Deployed (1-4)	Additional Assay(s) (1)	Cerba Research NGS †	Cerba Research IHC †	Cerba Research FISH †
EGFR	NGS, RT-PCR	Sanger sequencing, single gene	X	X
ALK	NGS, IHC, liquid biopsy	FISH (reflex), RT-PCR	X	X	X
ROS1	NGS	FISH (reflex), IHC (not recommended), RT-PCR	X	X	X
BRAF	NGS, RT-PCR, Sanger sequencing	IHC	X	X
KRAS	NGS, RT-PCR, Sanger sequencing		X	MEK1
MET	NGS, RNA-based NGS		X	X	X
RET	NGS, RNA-based NGS	FISH, RT-PCR	X	X	X
NTRK1/2/3	NGS, RNA-based NGS	FISH, IHC, PCR	X	X	X
EGFR T790M	NGS, liquid biopsy		X
PD-L1	IHC			X (clones 22C3, SP142, SP263 multiplexed)
HER2	NGS	Sanger sequencing, targeted PCR	X	X	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RT-PCR
Additional Assay(s) (1)	Sanger sequencing, single gene
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, IHC, liquid biopsy
Additional Assay(s) (1)	FISH (reflex), RT-PCR
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS
Additional Assay(s) (1)	FISH (reflex), IHC (not recommended), RT-PCR
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RT-PCR, Sanger sequencing
Additional Assay(s) (1)	IHC
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RT-PCR, Sanger sequencing
Additional Assay(s) (1)
Cerba Research NGS †	X
Cerba Research IHC †	MEK1
Cerba Research FISH †

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RNA-based NGS
Additional Assay(s) (1)
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RNA-based NGS
Additional Assay(s) (1)	FISH, RT-PCR
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, RNA-based NGS
Additional Assay(s) (1)	FISH, IHC, PCR
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS, liquid biopsy
Additional Assay(s) (1)
Cerba Research NGS †	X
Cerba Research IHC †
Cerba Research FISH †

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	IHC
Additional Assay(s) (1)
Cerba Research NGS †
Cerba Research IHC †	X (clones 22C3, SP142, SP263 multiplexed)
Cerba Research FISH †

Lung Cancer Biomarkers

Most Commonly Deployed (1-4)	NGS
Additional Assay(s) (1)	Sanger sequencing, targeted PCR
Cerba Research NGS †	X
Cerba Research IHC †	X
Cerba Research FISH †	X

1.NCCN guidelines 2024; 2.Bebb et al. Curr Oncol 2021; 3.Cabillic et al. ESMO Open 2018;3(6):e419; 4.Li et al. J Nat Cancer Center 2021; FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; NGS=next-generation sequencing

Histoprofile^® PD-L1 panel: PD-L1 (green), panCK (red), CD68 (orange)

1. World Health Organization: Cancer factsheets. URL [https://gco.iarc.fr/today/en/fact-sheets-cancers].

2. National Cancer Institute: NCI dictionary of cancer terms. URL [Definition of small cell lung cancer – NCI Dictionary of Cancer Terms – NCI].

3. American Cancer Society®: What is lung cancer? URL [What Is Lung Cancer? | Types of Lung Cancer | American Cancer Society].

4. Owen DH, Jaiyesimi IA, Leighl NB, Ismaila N, Florez N, Puri S, Schenk EL, Schneider BJ, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights. JCO Oncol Pract. 2024 Apr 8:OP2400177. doi: 10.1200/OP.24.00177. Epub ahead of print. PMID: 38588478.

5. National Comprehensive Cancer Network®: NCCN guidelines, treatment by cancer type. URL [Treatment by Cancer Type (nccn.org)].

6. Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053. PMID: 33467570; PMCID: PMC7903287.

Discover Our Expertise In Transforming Research For Your Lung Cancer Treatments

Fact Sheet – Advancing Your Solid Tumor Trials With Our Cutting-Edge Assay Portfolio

ASCO Abstract – Impact Of Overfixation On Actionable Biomarkers And Checkpoint Inhibitor (CKI) Targets With Immunohistochemistry (IHC) In A Patient Population With Non-small Cell Lung Cancer (NSCLC)I

White Paper – Precision Medicine For Non-Small Cell Lung Cancer (NSCLC) – Emerging Trends In Molecular Analysis

Poster – The Complexity Of Myeloid-derived Suppressor Cells In Non-Small Cell Lung Cancer: A Combinatorial Multiplex IHC And Flow Cytometry Approach

Presentation – Precision Medicine In Practice For NSCLC

Case Study – Evidence For The Utility Of AI In Ki-67 Quantification In Solid Tumors

Brochure – Cerba Research IHC Biomarkers

We recommend starting engagement with our scientific team early, such as at the protocol design phase, for optimal results. Reach out to us here.